Leveraging the Capabilities of Gamma Delta T Cells: Sebastian Wanless, MD, PhD
Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm, joins CGTL to discuss the company's development of chimeric co-stimulatory receptor T cells, as well as its clinical programs targeting cancers and infectious diseases.
"As far as I'm aware, this is unique. The are no other companies or researchers that we know of who have developed a product where the CAR only has the co-stimulatory domain." —Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm
The FDA recently granted orphan drug designation to TC BioPharm for its unmodified allogeneic gamma delta T cell (GDT) product TCB-002 (OmnImmune) for the potential treatment of relapsed/refractory acute myeloid leukemia (AML).
The UK-based cell therapy company, which applies chimeric antigen receptor (CAR) T-cell technology to GDT cells in an effort to make the therapeutic more selective, is also moving toward clinical trials for treatments for a range of cancers, as well as infectious diseases.
Joining CGTL to discuss updates on its clinical programs is Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
